A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Daxor Corporation is a medical device manufacturing company that offers additional biotech services, such as cryobanking, through its wholly-owned subsidiary, Scientific Medical Systems Corp. The main focus of Daxor Corporation has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. As further discussed in Note 12, the Company was found to be an investment company as defined by the Investment Company Act of 1940 by an Administrative Law Judge of the SEC. The Company plans to file a Form N-8A (Notification of Registration Filed Pursuant to Section 8(a) of the Investment Company Act of 1940) shortly after our Form 10-K for the year ended December 31, 2011 is filed. We have 90 days from when the N-8A is filed to file our Form N-2 which is the Registration Statement.
| Metric | TTM | FY2011 | FY2010 |
|---|---|---|---|
| Revenue | 0 | - | - |
| Net Income | -7.2M | -7.2M | 5.0M |
| EPS | $-1.70 | $-1.70 | $1.17 |
| Free Cash Flow | -6.6M | -6.6M | 5.4M |
| ROIC | -12.5% | -17.2% | 10.5% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 |
| Dividends/Share | $0.25 | $0.25 | $1.00 |
| Operating Income | -5.8M | -5.8M | -5.7M |
| Operating Margin | 0.0% | - | - |
| ROE | -19.8% | -17.3% | 10.6% |
| Shares Outstanding | 4M | 4M | 4M |
| Metric | 2010 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | 3.0M | 2.7M | 2.7M |
| SG&A | 3.5M | 3.9M | 3.9M |
| EBIT | -5.7M | -5.8M | -5.8M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | 5.0M | -7.2M | -7.2M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | 10.5% | -17.2% | -12.5% |
| ROE | 10.6% | -17.3% | -19.8% |
| ROA | 5.4% | -8.1% | -8.4% |
| Cash Flow | |||
| Op. Cash Flow | 5.7M | -6.5M | -6.5M |
| Free Cash Flow | 5.4M | -6.6M | -6.6M |
| Owner Earnings | 5.4M | -6.8M | -6.8M |
| CapEx | 325K | 123K | 123K |
| Maint. CapEx | 297K | 291K | 291K |
| Growth CapEx | 28K | 0 | 0 |
| D&A | 297K | 291K | 291K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 4.2M | 1.1M | 1.1M |
| Dividend Yield | 11.2% | 2.6% | 2.7% |
| Share Buybacks | 243K | 230K | 230K |
| Buyback Yield | 0.7% | 0.6% | 0.6% |
| Stock-Based Comp | N/A | 10K | 10K |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | -54M | -56M | 300K |
| Cash & Equiv. | 58K | 60K | 60K |
| Long-Term Debt | 300K | 244K | 244K |
| Debt/Equity | 0.01 | 0.01 | 0.01 |
| Interest Coverage | -88.5 | -33.0 | -33.0 |
| Equity | 47M | 36M | 36M |
| Total Assets | 91M | 86M | 86M |
| Total Liabilities | 44M | 50M | 50M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | 33M | 25M | 25M |
| Working Capital | 43M | 32M | 32M |
| Current Assets | 87M | 82M | 82M |
| Current Liabilities | 44M | 49M | 49M |
| Per Share Data | |||
| EPS | 1.17 | -1.70 | -1.70 |
| Owner EPS | 1.27 | -1.61 | -1.61 |
| Book Value | 11.07 | 8.57 | 8.57 |
| Cash Flow/Share | 1.34 | -1.54 | -1.63 |
| Dividends/Share | 1.00 | 0.25 | 0.25 |
| Shares Out. | 4.2M | 4.2M | 4.2M |
| Valuation | |||
| P/E Ratio | 7.1 | N/A | -5.5 |
| P/FCF | 6.6 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 0.8 | 1.0 | 1.1 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | 15.1% | -18.1% | -16.7% |
| Market Cap | 35M | 37M | 40M |
| Avg. Price | 8.87 | 9.50 | 9.38 |
| Year-End Price | 8.35 | 8.65 | 9.38 |
DAXOR CORP passes 1 of 9 quality checks, indicating weak fundamentals.
Total shareholder yield (dividends + buybacks) is 3.2%. At current prices, the estimated annualized return to fair value is -15.7%.
DAXOR CORP (DXR) has a 5-year average return on invested capital (ROIC) of -3.3%. This is below average and may indicate limited pricing power.
DAXOR CORP (DXR) has a market capitalization of $40M. It is classified as a small-cap stock.
Yes, DAXOR CORP (DXR) pays a dividend with a trailing twelve-month yield of 2.66%. The company also returns capital through share buybacks, with a buyback yield of 0.58%.
DAXOR CORP (DXR) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
DAXOR CORP (DXR) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
DAXOR CORP (DXR) reported earnings per share (EPS) of $-1.70 in its most recent fiscal year.
DAXOR CORP (DXR) has a return on equity (ROE) of -17.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for DAXOR CORP (DXR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DAXOR CORP (DXR) has a book value per share of $8.57, based on its most recent annual SEC filing.
No recent press releases.